Rybrevant Faspro Injection
Product Images NDC 57894-522

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rybrevant Faspro (NDC 57894-522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rybrevant 01)

A Kaplan-Meier survival curve chart comparing the proportion of patients surviving without disease progression over time in months. Two treatment groups are shown: intravenous amivantamab plus lazertinib, and osimertinib. The plot includes numbers at risk over time for each treatment group, illustrating differences in progression-free survival.*

FDA Label Image

Figure 2 (Rybrevant 02)

A survival curve chart comparing the proportion of patients surviving over months between two treatments: intravenous amivantamab plus lazertinib and osimertinib. The x-axis represents time in months (0 to 51), and the y-axis represents the proportion surviving (0 to 1). Below the x-axis, a table shows the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure 3 (Rybrevant 03)

A Kaplan-Meier survival curve chart depicting the proportion of subjects surviving without disease progression over time in months. Two groups are compared: R-CP (depicted with open circles) and CP (depicted with solid triangles). The x-axis shows time in months (0 to 15), and the y-axis shows the proportion surviving without progression from 0 to 1. A table below indicates the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 4 (Rybrevant 04)

A Kaplan-Meier survival plot comparing the proportion of patients surviving without progression over 24 months. Two groups are shown: R-CP (marked with circles) and CP (marked with triangles). The x-axis represents months, and the y-axis shows the proportion surviving without progression. Below the graph is a table indicating the number of patients at risk at various time points for each group.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Carton packaging label for Rybrevant Faspro injection (amivantamab and hyaluronidase-lpuj) 1600 mg and 20,000 units/10 mL (160 mg and 2,000 units/mL) for subcutaneous injection. The label states it is for healthcare provider use only and contains a 10 mL single-dose vial. Manufacturer is Janssen Biotech, Inc., a Johnson & Johnson company. Storage instructions and ingredient details are included, with a barcode and lot information area visible.*

FDA Label Image

Principal Display Panel (14 mL Vial Carton)

Packaging label for Rybrevant Faspro injection, a subcutaneous human prescription drug containing 2,240 mg amivantamab and 28,000 units hyaluronidase per 14 mL vial. The label states the product is for subcutaneous injection by a healthcare provider only and includes storage instructions, manufacturer Janssen Biotech, Inc., and barcode information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.